Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases

IUBMB Life

Volumn 59, Issue 4-5, 2007, Pages 332-345

  Ferreira, Sergio T ^a   Vieira, Marcelo N N ^a   De Felice, Fernanda G ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid disorders; Soluble amyloid oligomers

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA SYNUCLEIN; AMPA RECEPTOR; AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; DESMIN; HUNTINGTIN; IMMUNOGLOBULIN LIGHT CHAIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; PREALBUMIN; PRION PROTEIN; STEFIN; TOXIN; VOLTAGE GATED CALCIUM CHANNEL;

ALZHEIMER DISEASE; CALCIUM HOMEOSTASIS; CELL FUNCTION; CELL SURFACE; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; CYTOTOXICITY; EXTRACELLULAR CALCIUM; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL AMYLOIDOSIS; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; KURU; MYOCLONUS EPILEPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PROCESSING; TISSUE SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CALCIUM; HUMANS; NEURONS; OXIDATIVE STRESS; PROTEIN STRUCTURE, QUATERNARY; PROTEINS; RECEPTORS, CELL SURFACE; TAU PROTEINS; TAUOPATHIES;

ANIMALIA;

EID: 34248547813     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1080/15216540701283882     Document Type: Conference Paper

References (163)

1. Ferreira, S. T., De Felice, F. G., and Chapeaurouge, A. (2006) Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins. Cell Biochem. Biophys. 44, 539-548.
2. Stefani, M., and Dobson, C. M. (2003) Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678-699.
3. Pepys, M. B., Hawkins, P.N., Booth, D. R., Vigushin, D.M., Tennent, G. A., Soutar, A. K., Totty, N., Nguyen, O., Blake, C. C., Terry, C. J., Feest, T. G., Zalin, A.M., and Hsuan, J. J. (1993)Human lysozyme gene mutations cause hereditary systemicamyloidosis. Nature 362, 553-557.
4. Maloy, A. L., Longnecker, D. S., and Greenberg, E. R. (1981) The relation of islet amyloid to the clinical type of diabetes. Hum. Pathol. 12, 917-922.
5. Terry, R. D., Gonatas, N. K., and Weiss, M. (1964) Ultrastructural studies in Alzheimer's presenile dementia. Am. J. Pathol. 44, 269-297.
6. Dobson, C. M. (2003) Protein folding and misfolding. Nature 426, 884-890.
7. Gustavsson, A., Engstrom, U., and Westermark, P. (1991) Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro. Biochem. Biophys. Res. Commun. 175, 1159-1164.
8. Westermark, P., Engstrom, U., Johnson, K. H., Westermark, G. T., and Betsholtz, C. (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87, 5036-5040.
9. Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C., and Pepys, M. B. (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793.
10. Castano, E. M., Ghiso, J., Prelli, F., Gorevic, P. D., Migheli, A., and Frangione, B. (1986) In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease beta-protein. Biochem. Biophys. Res. Commun. 141, 782-789.
11. Lorenzo, A., and Yankner, B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247.
12. Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O., and Tagliavini, F. (1993) Neurotoxicity of a prion protein fragment. Nature 362, 543-546.
13. Lopes, D. H., Colin, C., Degaki, T. L., de Sousa, A. C., Vieira, M. N., Sebollela, A., Martinez, A. M., Bloch, C. Jr, Ferreira, S. T., and Sogayar, M. C. (2004) Amyloidogenicity and cytotoxicity of recombinant mature human islet amyloid polypeptide (rhIAPP). J. Biol. Chem. 279, 42803-42810.
14. Shimada, K., Maeda, S., Murakami, T., Nishiguchi, S., Tashiro, F., Yi, S., Wakasugi, S., Takahashi, K., and Yamamura, K. (1989) Transgenic mouse model of familial amyloidotic polyneuropathy. Mol. Biol. Med. 6, 333-343.
15. Scott, M., Foster, D., Mirenda, C., Serban, D., Coufal, F., Walchli, M., Torchia, M., Groth, D., Carlson, G., DeArmond, S. J., Westaway, D., and Prusiner S. B. (1989) Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59, 847-857.
16. Wirak, D. O., Bayney, R., Ramabhadran, T. V., Fracasso, R. P., Hart, J. T., Hauer, P. E., Hsiau, P., Pekar, S. K., Scangos, G. A., Trapp, B. D., and Unterbeck A. J. (1991) Deposits of amyloid beta protein in the central nervous system of transgenic mice. Science 253, 323-325.
17. Quon, D., Wang, Y., Catalano, R., Scardina, J. M., Murakami, K., and Cordell, B. (1991) Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352, 239-241.
18. Yagui, K., Yamaguchi, T., Kanatsuka, A., Shimada, F., Huang, C. I., Tokuyama, Y., Ohsawa, H., Yamamura, K., Miyazaki, J., Mikata, A., et al. (1995) Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. Eur. J. Endocrinol. 132, 487-496.
19. Budka, H. (2003) Neuropathology of prion diseases. Br. Med. Bull. 66, 121-130.
20. Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., and Peck, A. (1988) Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138-144.
21. Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., and Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580.
22. Giannakopoulos, P., Herrmann, F. R., Bussiere, T., Bouras, C., Kovari, E., Perl, D. P., Morrison, J. H., Gold, G., and Hof, P. R. (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500.
23. Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., and Ashe, K. H. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331-6335.
24. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457.
25. Verchere, C. B., D'Alessio, D. A., Palmiter, R. D., Weir, G. C., Bonner-Weir, S., Baskin, D. G., and Kahn, S. E. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA 93, 3492-3496.
26. Janson, J., Ashley, R. H., Harrison, D., McIntyre, S., and Butler, P. C. (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491-498.
27. Butler, A. E., Jang, J., Gurlo, T., Carty, M. D., Soeller, W. C., and Butler, P. C. (2004) Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53, 1509-1516.
28. Sousa, M. M., Cardoso, I., Fernandes, R., Guimaraes, A., and Saraiva, M. J. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159, 1993-2000.
29. Teng, M. H., Yin, J. Y., Vidal, R., Ghiso, J., Kumar, A., Rabenou, R., Shah, A., Jacobson, D. R., Tagoe, C., Gallo, G., and Buxbaum J. (2001) Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab. Invest. 81, 385-396.
30. Sousa, M., Du, M., Yan, S., Fernandes, R., Guimaraes, A., Stern, D., and Saraiva, M. J. (2001) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 21, 7576-7586.
31. Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli,M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P. R., Rimmer, E., Scazufca, M.; Alzheimer's Disease International. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
32. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
33. Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S. M., Wang, S., Walker, D., Zhao, J., McConlogue, L., and John, V. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-450.
34. Selkoe, D. J., Yamazaki, T., Citron, M., Podlisny, M. B., Koo, E. H., Teplow, D. B., and Haass, C. (1996) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. NY Acad. Sci. 777, 57-64.
35. Wolfe, M. S. (2006) The gamma-secretase complex: membraneembedded proteolytic ensemble. Biochemistry 45, 7931-7939.
36. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513-517.
37. Tanzi, R. E., and Bertram, L. (2001) New frontiers in Alzheimer's disease genetics. Neuron 32, 181-184.
38. Hardy, J. A., and Higgins, G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
39. Klein, W. L., Krafft, G. A., and Finch, C. E. (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224.
40. Tabaton, M., Nunzi, M. G., Xue, R., Usiak, M., Autilio-Gambetti, L., and Gambetti, P. (1994) Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun. 200, 1598-1603.
41. Frackowiak, J., Zoltowska, A., and Wisniewski, H. M. (1994) Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. J. Neuropathol. Exp. Neurol. 53, 637-645.
42. Kuo, Y. M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., and Roher, A. E. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081.
43. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.
44. Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., and Klein, W. L. (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417-10422.
45. Georganopoulou, D. G., Chang, L., Nam, J. M., Thaxton, C. S., Mufson, E. J., Klein, W. L., and Mirkin, C. A. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 102, 2273-2276.
46. Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., Krafft, G. A., and Klein, W. L. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24, 10191-10200.
47. Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., and LaFerla, F. M. (2006) Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 281, 1599-1604.
48. Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., and Disterhoft, J. F. (2006) Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23, 251-260.
49. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) A specific amyloidbeta protein assembly in the brain impairs memory. Nature 440, 352-357.
50. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Diffusible., nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453.
51. Klein, W. L., Lacor, P. N., De Felice, F. G., and Ferreira, S. T. (2007) Molecules that disrupt memory circuits in Alzheimer's disease: the attack on synapses by Aβ oligomers (ADDLs). In Memories: Molecules and Circuits, (Bontempi, B., Silva, A., Christen, Y., eds.), Paris, Springer-Verlag (in press).
52. Huang, T. H., Yang, D. S., Plaskos, N. P., Go, S., Yip, C. M., Fraser, P. E., and Chakrabartty, A. (2000) Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol. 297, 73-87.
53. Bitan, G., Lomakin, A., and Teplow, D. B. (2001) Amyloid betaprotein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276, 35176-35184.
54. Ward, R. V., Jennings, K. H., Jepras, R., Neville, W., Owen, D. E., Hawkins, J., Christie, G., Davis, J. B., George, A., Karran, E. H., and Howlett, D. R. (2000) Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 348, 137-144.
55. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
56. Podlisny, M. B., Ostaszewski, B. L., Squazzo, S. L., Koo, E. H., Rydell, R. E., Teplow, D. B., and Selkoe, D. J. (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270, 9564-9570.
57. Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M. B., Teplow, D. B., Haass, C., Seubert, P., Koo, E. H., and Selkoe D. J. (1997) Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272, 7977-7982.
58. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
59. Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., and Glabe, C. G. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17294-17300.
60. Kelly, B. L., and Ferreira, A. (2006) beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J. Biol. Chem. 281, 28079-28089.
61. Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., and Selkoe, D. J. (2006) Effects of secreted oligomers of amyloid betaprotein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477-492.
62. Deshpande, A., Mina, E., Glabe, C., and Busciglio, J. (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26, 6011-6018.
63. Wang, H. W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., and Trommer, B. L. (2002) Soluble oligomers of beta amyloid (1-42) inhibit longterm potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-140.
64. De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., Chen-Dodson, E., Kinney, G. G., and Klein, W. L. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Submitted.
65. De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., and Klein, W. L. Aβ oligomers induce neuronal oxidative stress through an NMDA receptor-dependent mechanism that is blocked by the Alzheimer's drug memantine. Submitted.
66. Chinopoulos, C., and Adam-Vizi, V. (2006) Calcium., mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J. 273, 433-450.
67. Mattson, M. P., and Chan, S. L. (2003) Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34, 385-397.
68. LaFerla, F. M. (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3, 862-872.
69. Bobich, J. A., Zheng, Q., and Campbell, A. (2004) Incubation of nerve endings with a physiological concentration of Abeta1-42 activates CaV2. 2(N-Type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. J. Alzheimers Dis. 6, 243-255.
70. Podlisny, M. B., Walsh, D. M., Amarante, P., Ostaszewski, B. L., Stimson, E. R., Maggio, J. E., Teplow, D. B., and Selkoe, D. J. (1998) Oligomerization of endogenous and synthetic amyloid betaprotein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37, 3602-3611.
71. Pollard, H. B., Rojas, E., and Arispe, N. (1993) A new hypothesis for the mechanism of amyloid toxicity., based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes. Ann. NY Acad. Sci. 695, 165-168.
72. Pollard, H. B., Rojas, E., and Arispe, N. (1995) Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Cell. Mol. Neurobiol. 15, 513-526.
73. Mattson, M. P. (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639.
74. Pratico, D., and Delanty N. (2000) Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 109, 577-585.
75. Zhu, X., Lee, H. G., Casadesus, G., Avila, J., Drew, K., Perry, G., and Smith, M. A. (2005) Oxidative imbalance in Alzheimer's disease. Mol. Neurobiol. 31, 205-217.
76. Zhu, X., Perry, G., Moreira, P. I., Aliev, G., Cash, A. D., Hirai, K., and Smith, V. A. (2006) Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J. Alzheimers Dis. 9, 147-153.
77. Serrano, F., and Klann, E. (2004) Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res. Rev. 3, 431-443.
78. Sponne, I., Fifre, A., Drouet, B., Klein, C., Koziel, V., Pincon-Raymond, M., Olivier, J. L., Chambaz. J., and Pillot, T. (2003) Apoptotic neuronal cell death induced by the non-fibrillar amyloidbeta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J. Biol. Chem. 278, 3437-3445.
79. Florent, S., Malaplate-Armand, C., Youssef, I., Kriem, B., Koziel, V., Escanye, M. C., Fifre, A., Sponne, I., Leininger-Muller, B., Olivier, J. L., Pillot, T., and Oster, T. (2006) Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J. Neurochem. 96, 385-395.
80. Mazur-Kolecka, B., Golabek, A., Nowicki, K., Flory, M., and Frackowiak, J. (2006) Amyloid-beta impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol. Aging 27, 1181-1192.
81. Louzada, P. R. Jr., Paula Lima, A. C., de Mello, F. G., and Ferreira, S. T. (2001) Dual role of glutamatergic neurotransmission on amyloid beta(1-42) aggregation and neurotoxicity in embryonic avian retina. Neurosci. Lett. 301, 59-63.
82. Louzada, P. R., Lima, A. C., Mendonca-Silva, D. L., Noel, F., De Mello, F. G., and Ferreira, S. T. (2004) Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J. 18, 511-518.
83. Lima, A. C., Louzada, P. R., De Mello, F. G., and Ferreira, S. T. (2003) Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? Neurotox. Res. 5, 323-327.
84. Paula-Lima, A. C., De Felice, F. G., Brito-Moreira, J., and Ferreira, S. T. (2005) Activation of GABA(A) receptors by taurine and muscimol blocks the neurotoxicity of beta-amyloid in rat hippocampal and cortical neurons. Neuropharmacology 49, 1140-1148.
85. Roselli, F., Tirard, M., Lu, J., Hutzler, P., Lamberti, P., Livrea, P., Morabito, M., and Almeida, O. F. (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J. Neurosci. 25, 11061-11070.
86. Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., and Greengard, P. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 1051-1058.
87. Goto, Y., Niidome, T., Akaike, A., Kihara, T., and Sugimoto, H. (2006) Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. Biochem. Biophys. Res. Commun. 351, 259-265.
88. Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., and Klein, W. L. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796-807.
89. Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., and Malinow, R. (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843.
90. Wang, H. Y., Lee, D. H., D'Andrea, M. R., Peterson, P. A., Shank, R. P., and Reitz, A. B. (2000) beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 275, 5626-5632.
91. Wu, J., Kuo, Y. P., George, A. A., Xu, L., Hu, J., and Lukas, R. J. (2004) beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J. Biol. Chem. 279, 37842-37851.
92. Pettit, D. L., Shao, Z., and Yakel, J. L. (2001) beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 21, RC120(1-5).
93. Magdesian, M. H., Nery, A. A., Martins, A. H., Juliano, M. A., Juliano, L., Ulrich, H., and Ferreira, S. T. (2005) Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta. J. Biol. Chem. 280, 31085-31090.
94. Avila, J. (2006) Tau protein, the main component of paired helical filaments. J. Alzheimers Dis. 9, 171-175.
95. Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M., and Yankner, B. A. (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4, 827-831.
96. Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R. M. (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
97. Lewis, J., Dickson, D. W., Lin, W. L., Chisholm, L., Corral, A., Jones, G., Yen, S. H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M., and McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
98. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B. P., and LaFerla, F. M. (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24, 1063-1070.
99. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla F. M. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
100. Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., and LaFerla, F. M. (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332.
101. Naslund, J., Haroutunian, V., Mohs, R., Davis, K. L., Davies, P., Greengard, P., and Buxbaum, J. D. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
102. Hoshi, M., Sato, M., Matsumoto, S., Noguchi, A., Yasutake, K., Yoshida, N., and Sato, K. (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. USA 100, 6370-6375.
103. Ma, Q. L., Lim, G. P., Harris-White, M. E., Yang, F., Ambegaokar, S. S., Ubeda, O. J., Glabe, C. G., Teter, B., Frautschy, S. A., and Cole, G. M. (2006) Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J. Neurosci. Res. 83, 374-384.
104. King, M. E., Kan, H. M., Baas, P. W., Erisir, A., Glabe, C. G., and Bloom, G. S. (2006) Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J. Cell Biol. 175, 541-546.
105. Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002) Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 99, 6364-6369.
106. Gouras, G. K., Almeida, C. G., and Takahashi, R. H. (2005) Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 26, 1235-1244.
107. Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., and Gouras, G. K. (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869-1879.
108. Takahashi, R. H., Almeida, C. G., Kearney, P. F., Yu, F., Lin, M. T., Milner, T. A., and Gouras, G. K. (2004) Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592-3599.
109. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., and Stefani,M. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
110. Bucciantini, M., Calloni, G., Chiti, F., Formigli, L., Nosi, D., Dobson, C. M., and Stefani, M. (2004) Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 279, 31374-31382.
111. Vieira, M. N., Germano, L. F., Saraiva, L. M., Sebollela, A., Martinez, A. M., Houzel, J. C., Felice, F. G., and Ferreira, S. T. Soluble lysozyme oligomers induce Alzheimer's disease-type tau hyperphosphorylation and neurodegeneration. 155-179.
112. Frasier, M., Walzer, M., McCarthy, L., Magnuson, D., Lee, J. M., Haas, C., Kahle, P., and Wolozin B. (2005) Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp. Neurol. 192, 274-287.
113. Bautista, M. J., Gutierrez, J., Salguero, F. J., Fernandez de Marco, M. M., Romero-Trevejo, J. L., and Gomez-Villamandos, J. C. (2006) BSE infection in bovine PrP transgenic mice leads to hyperphosphorylation of tau-protein. Vet. Microbiol. 115, 293-301.
114. Martins, S. M., Frosoni, D. J., Martinez, A. M., De Felice, F. G., and Ferreira, S. T. (2006) Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231). J. Biol. Chem. 281, 26121-26128.
115. Gobbi, M., Colombo, L., Morbin, M., Mazzoleni, G., Accardo, E., Vanoni, M., Del Favero, E., Cantu, L., Kirschner, D,A., Manzoni, C., Beeg, M., Ceci, P., Ubezio, P., Forloni, G., Tagliavini, F., and Salmona, M. (2006) Gerstmann-Straussler-Scheinker disease amyloid protein polymerizes according to the "dock-and-lock" model. J. Biol. Chem. 281, 843-849.
116. Apetri, A. C., Vanik, D. L., and Surewicz, W. K. (2005) Polymorphism at residue 129 modulates the conformational conversion of the D178N variant of human prion protein 90-231. Biochemistry 44, 15880-15888.
117. Vanik, D. L., and Surewicz, W. K. (2002) Disease-associated F198S mutation increases the propensity of the recombinant prion protein for conformational conversion to scrapie-like form. J. Biol. Chem. 277, 49065-49070.
118. Novitskaya, V., Bocharova, O. V., Bronstein, I., and Baskakov, I. V. (2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281, 13828-13836.
119. Korth, C., Stierli, B., Streit, P., Moser, M., Schaller, O., Fischer, R., Schulz-Schaeffer, W., Kretzschmar, H., Raeber, A., Braun, U., Ehrensperger, F., Hornemann, S., Glockshuber, R., Riek, R., Billeter, M., Wuthrich, K., and Oesch, B. (1997) Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 390, 74-77.
120. Redecke, L., Bergen, M. V., Clos, J., Konarev, P. V., Svergun, D. I., Fittschen, U. E., Broekaert, J. A., Bruns, O., Georgieva, D., Mandelkow, E., Genov, N., and Betzel, C. (2007) Structural characterization of beta-sheeted oligomers formed on the pathway of oxidative prion protein aggregation in vitro. J. Struct. Biol. 157, 308-320.
121. Bagriantsev, S., and Liebman, S. (2006) Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol. 26, 4:32.
122. Tahiri-Alaoui, A., Sim, V. L., Caughey, B., and James, W. (2006) Molecular heterosis of prion protein beta-oligomers. A potential mechanism of human resistance to disease. J. Biol. Chem. 281, 34171-34178.
123. Kawai-Noma, S., Ayano, S., Pack, C. G., Kinjo, M., Yoshida, M., Yasuda, K., and Taguchi, H. (2006) Dynamics of yeast prion aggregates in single living cells. Genes Cells 11, 1085-1096.
124. Vasan, S., Mong, P. Y., and Grossman, A. (2006) Interaction of prion protein with small highly structured RNAs: detection and characterization of PrP-oligomers. Neurochem. Res. 31, 629-637.
125. Zheng, J., Ma, B., Tsai, C. J., and Nussinov, R. (2006) Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35. Biophys. J. 91, 824-833.
126. Ulrih, N. P., Skrt, M., Veranic, P., Galvani, V., Vranac, T., and Curin Serbec, V. (2006) Oligomeric forms of peptide fragment PrP(214-226) in solution are preferentially recognized by PrP(Sc)-specific antibody. Biochem. Biophys. Res. Commun. 344, 1320-1326.
127. Silveira, J. R., Raymond, G. J., Hughson, A. G., Race, R. E., Sim, V. L., Hayes, S. F., and Caughey, B. (2005) The most infectious prion protein particles. Nature 437, 257-261.
128. Vendrely, C., Valadie, H., Bednarova, L., Cardin, L., Pasdeloup, M., Cappadoro, J., Bednar, J., Rinaudo, M., and Jamin, M. (2005) Assembly of the full-length recombinant mouse prion protein I. Formation of soluble oligomers. Biochim. Biophys. Acta 1724, 355-366.
129. Dorandeu, A., Wingertsmann, L., Chretien, F., Delisle, M. B., Vital, C., Parchi, P., Montagna, P., Lugaresi, E., Ironside, J. W., Budka, H., Gambetti, P., and Gray, F. (1998) Neuronal apoptosis in fatal familial insomnia. Brain Pathol. 8, 531-537.
130. Piao, Y. S., Kakita, A., Watanabe, H., Kitamoto, T., and Takahashi, H. (2005) Sporadic fatal insomnia with spongiform degeneration in the thalamus and widespread PrPSc deposits in the brain. Neuropathology 25, 144-149.
131. Armstrong, R. A., Lantos, P. L., Ironside, J. W., and Cairns, N. J. (2003) Spatial correlation between the vacuolation, prion protein, deposition and surviving neurons in patients with Creutzfeldt-Jakob disease (vCJD). J. Neural Transm. 110, 1303-1311.
132. Chiesa, R., and Harris, D. A. (2001) Prion diseases: what is the neurotoxic molecule? Neurobiol. Dis. 8, 743-763.
133. Conway, K. A., Harper, J. D., and Lansbury, P. T. Jr. (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563.
134. Goldberg, M. S., and Lansbury, P. T. Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, 115-119.
135. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., and Lansbury, P. T. Jr. (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102.
136. Klucken, J., Outeiro, T. F., Nguyen, P., McLean, P. J., and Hyman, B. T. (2006) Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 20, 2050-2057.
137. Mazzulli, J. R., Mishizen, A. J., Giasson, B. I., Lynch, D. R., Thomas, S. A., Nakashima, A., Nagatsu, T., Ota, A., and Ischiropoulos, H. (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068-10078.
138. Lee, C. H., Kim, H. J., Lee, J. H., Cho, H. J., Kim, J., Chung, K. C., Jung, S., and Paik, S. R. (2006) Dequalinium-induced protofibril formation of alpha-synuclein. J. Biol. Chem. 281, 3463-3472.
139. Yamin, G., Munishkina, L. A., Karymov, M. A., Lyubchenko, Y. L., Uversky, V. N., and Fink, A. L. (2005) Forcing nonamyloidogenic beta-synuclein to fibrillate. Biochemistry 44, 9096-9107.
140. El-Agnaf, O. M., Paleologou, K. E., Greer, B., Abogrein, A. M., King, J. E., Salem, S. A., Fullwood, N. J., Benson, F. E., Hewitt, R., Ford, K. J., Martin, F. L., Harriott, P., Cookson, M. R., and Allsop, D. (2004) A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18, 1315-1317.
141. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A.,
142. Sharon, R., Bar-Joseph, I., Mirick, G. E., Serhan, C. N., and Selkoe, D. J. (2003) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J. Biol. Chem. 278, 49874-49881.
143. Tompkins, M. M., and Hill, W. D. (1997) Contribution of somal Lewy bodies to neuronal death. Brain Res. 775, 24-29.
144. Mukai, H., Isagawa, T., Goyama, E., Tanaka, S., Bence, N. F., Tamura, A., Ono, Y., and Kopito, R. R. (2005) Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc. Natl. Acad. Sci. USA 102, 10887-10892.
145. Hoffner, G., Island, M. L., and Djian, P. (2005) Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J. Neurochem. 95, 125-136.
146. Dunah, A. W., Jeong, H., Griffin, A., Kim, Y. M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243.
147. Yu, Z. X., Li, S. H., Nguyen, H. P., and Li, X. J. (2002) Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet. 11, 905-914.
148. Karpuj, M. V., Garren, H., Slunt, H., Price, D. L., Gusella, J., Becher, M. W., and Steinman, L. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. USA 96, 7388-7393.
149. Manderluh, G., Gutierrez-Aguirre, I., Rabzelj, S., Ceru, S., Kopitar-Jerala, N., Macek, P., Turk, V., and Zerovnik, E. (2005) Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity. FEBS J. 272, 3042-3051.
150. Janson, J., Ashley, R. H., Harrison, D., McIntyre, S., and Butler, P. C. (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491-498.
151. Konarkowska, B., Aitken, J. F., Kistler, J., Zhang, S., and Cooper, G. J. (2006) The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. FEBS J. 273, 3614-3624.
152. Yan, L. M., Tatarek-Nossol, M., Velkova, A., Kazantzis, A., and Kapurniotu, A. (2006) Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. USA 103, 2046-2051.
153. Butler, A. E., Jang, J., Gurlo, T., Carty, M. D., Soeller, W. C., and Butler, P. C. (2004) Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53, 1509-1516.
154. De Felice, F. G., Vieira, M. N., Meirelles, M. N., Morozova-Roche, L. A., Dobson, C. M., and Ferreira, S. T. (2004) Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure. FASEB J. 18, 1099-1101.
155. Hou, X., Parkington, H. C., Coleman, H. A., Mechler, A., Martin, L. L., Aguilar, M. I., and Small, D. H. (2007) Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J. Neurochem. 100, 446-457.
156. Souillac, P. O., Uversky, V. N., Millett, I. S., Khurana, R., Doniach, S., and Fink, A. L. (2002) Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off-pathway oligomer at acidic pH. J. Biol. Chem. 277, 12666-12679.
157. Souillac, P. O., Uversky, V. N., and Fink, A. L. (2003) Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN. Biochemistry 42, 8094-8104.
158. Buxbaum, J., and Gallo, G. (1999) Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain., heavy-chain, and light- and heavy-chain deposition diseases. Hematol. Oncol. Clin. North Am. 13, 1235-1248.
159. Relini, A., Rolandi, R., Bolognesi, M., Aboudan, M., Merlini, G., Bellotti, V., and Gliozzi, A. (2004) Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. Biochim. Biophys. Acta 1690, 33-41.
160. Sanbe, A., Osinska, H., Saffitz, J. E., Glabe, C. G., Kayed, R., Maloyan, A., and Robbins, J. (2004) Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc. Natl. Acad. Sci. USA 101, 10132-10136.
161. Sanbe, A., Osinska, H., Villa, C., Gulick, J., Klevitsky, R., Glabe, C. G., Kayed, R., and Robbins, J. (2005) Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc. Natl. Acad. Sci. USA 102, 13592-13597.
162. Smith, D. P., and Radford, S. E. (2001) Role of the single disulphide bond of beta(2)-microglobulin in amyloidosis in vitro. Protein Sci. 10, 1775-1784.
163. Eakin, C. M., Attenello, F. J., Morgan, C. J., and Miranker, A. D. (2004) Oligomeric assembly of native-like precursors precedes amyloid formation by beta-2 microglobulin. Biochemistry 43, 7808-7815.